5 to -1 °C, VSM% >50%, SEC > 1.5 mS/cm, bulk resistivity less then 12 Ω m with shallow groundwater levels less then 3 m below ground level (bgl) are potentially contaminated perennial seepage sources. Impermeable sheet piles have been installed across the groundwater flow direction to control the seepage up to 1.5 m bgl, where groundwater frequently intercepts land surface. The quantity of dry season groundwater seepage has been declined by 79.2% after these interventions, which in turn minimized the treatment cost of 1,96,283 USD/year and improved the downstream ecosystem.The development of an eco-friendly and reliable process for the production of nanomaterials is essential to overcome the toxicity and exorbitant cost of conventional methods. As such, a facile and green synthesis method is introduced for the preparation of lignin mediated silver nanoparticles (L-Ag NPs). This is produced by reducing Ag precursors using lignin biopolymers which are formulated by pulsed laser irradiation and an ultrasonication process. Lignin operates as both a reducing and stabilizing agent. The various analytical techniques of ultraviolet-visible spectroscopy, transmission electron microscope and X-ray diffractometer studies were employed to verify the formation of non-aggregated spherical L-Ag NPs with an average size as small as 7-8 nm. The selective sensing capability of the synthesized L-Ag NPs was examined for the detection of hydrogen peroxide and mercury ions in an aqueous environment. Furthermore, the superior catalytic performance of L-Ag NPs was demonstrated by the rapid conversion of toxic 4-nitrophenol and nitrobenzene as targeted pollutants to the corresponding amino compounds. A plausible catalytic reduction mechanism for the removal of toxic nitro-organic pollutants over L-Ag NPs is proposed. This research coincides with existing studies and affirms that L-Ag NPs are an effective sensor that be applied as a catalytic material within environmental remediation and also alternative biomedical applications.In France, cancer treatments are mainly provided in hospitals, which are expensive and crowded. Health decision-makers therefore want to develop alternative structures such as home care and local health centres. To elicit cancer patients' preferences for home, local health centre, or hospital, and analyze factors affecting these choices patients' characteristics, experiences of care, expectations and perceptions of cancer management. We developed a decision aid composed of 1) information on the 3 options 2) a questionnaire to measure preferences; 3) a questionnaire on sociodemographics and experiences of care, 386 patients participated in the survey. hospital was the preferred option for 71 % of the participants, especially for complicated care, followed by home care (24 %) and local health centres (5%). Epalrestat chemical structure Main reasons for preferring hospital were the wish to separate home life and place of care, wanting to avoid being a burden on their relatives. Reasons influencing a preference for home care were wanting to avoid trips, maintain their lifestyle, and finding hospitals frightening. Neither socio-demographics nor even experience of care seemed to explain preferences. A quarter of patients preferred home care, which is highly disproportionate to the home care currently available. This suggests that hindrances to developing alternatives to hospital do not come from patients' reluctance to make use of them, but rather from healthcare providers' objections.A quarter of patients preferred home care, which is highly disproportionate to the home care currently available. This suggests that hindrances to developing alternatives to hospital do not come from patients' reluctance to make use of them, but rather from healthcare providers' objections.Abuse of antibiotics has led to the emergence of drug-resistant pathogens. Methicillin-resistant Staphylococcus aureus (MRSA) was reported just two years after the clinical use of methicillin, which can cause severe infections with high morbidity and mortality in both community and hospital. The treatment of MRSA infection is greatly challenging since it has developed the resistance to almost all types of antibiotics. As such, it is of great significance and importance to develop novel therapeutic approaches. The fast development of nanotechnology provides a promising solution to this dilemma. Functional nanomaterials and nanoparticles can act either as drug carriers or as antibacterial agents for antibacterial therapy. Herein, we aim to provide a comprehensive understanding of the drug resistance mechanisms of MRSA and discuss the potential applications of some functionalized nanomaterials in anti-MRSA therapy. Also, the concerns and possible solutions for the nanomaterials-based anti-MRSA therapy are discussed.A series of novel CA-4 analogs as dual inhibitors of tubulin polymerization and PD-1/PD-L1 were designed, synthesized and bio-evaluated. Among them, compound TP5 exhibited strongest inhibitory effects against five cancer cell lines with an IC50 value of 800 nM in HepG2 cells. In addition, mechanism studies revealed that TP5 could effectively inhibit tubulin polymerization, suppress HepG2 cells migration and colony formation, and cause cell arrest at G2/M phase and induce apoptosis. Furthermore, TP5 exhibited moderate anti-PD-1/PD-L1 activity with IC50 values of 48.76 μM in a homogenous time-resolved fluorescence (HTRF) assay. In vivo efficacy studies indicated that TP5 could significantly suppress tumor growth in an immune checkpoint humanized mouse model with a Tumor Growth Suppression (TGI) of 57.9% at 100 mg/kg without causing significant toxicity. Moreover, TP5 did not cause in vivo cardiotoxicity in BALB/c mice. These results suggest that the novel CA-4 analogs may serve as a starting point for developing more potent dual inhibitors of tubulin polymerization and PD-1/PD-L1.Designer Receptors Exclusively Activated by Designer Drugs (DREADD) are a preclinical chemogenetic approach with clinical potential for various disorders. In vivo visualization of DREADDs has been achieved with positron emission tomography (PET) using 11C radiotracers. The objective of this study was to develop DREADD radiotracers labeled with 18F for a longer isotope half-life. A series of non-radioactive fluorinated analogs of clozapine with a wide range of in vitro binding affinities for the hM3Dq and hM4Di DREADD receptors has been synthesized for PET. Compound [18F]7b was radiolabeled via a modified 18F-deoxyfluorination protocol with a commercial ruthenium reagent. [18F]7b demonstrated encouraging PET imaging properties in a DREADD hM3Dq transgenic mouse model, whereas the radiotracer uptake in the wild type mouse brain was low. [18F]7b is a promising long-lived alternative to the DREADD radiotracers [11C]clozapine ([11C]CLZ) and [11C]deschloroclozapine ([11C]DCZ).